Treatment of COVID-19 olfactory dysfunction with olfactory training, palmitoylethanolamide with luteolin, or combined therapy : a blinded controlled multicenter randomized trial
© 2023. The Author(s)..
PURPOSE: Few evidence-based therapies are available for chronic olfactory dysfunction after COVID-19. This study investigated the relative efficacy of olfactory training alone, co-ultramicronized palmitoylethanolamide with luteolin (um-PEA-LUT, an anti-neuroinflammatory supplement) alone, or combined therapy for treating chronic olfactory dysfunction from COVID-19.
METHODS: This double-blinded controlled, placebo-controlled multicenter randomized clinical trial was conducted in 202 patients with persistent COVID-19 olfactory dysfunction of > 6 month duration. After a screening nasal endoscopy, patients were randomized to: (1) olfactory training and placebo; (2) once daily um-PEA-LUT alone; (3) twice daily um-PEA-LUT alone; or (4) combination of once daily um-PEA-LUT with olfactory training. Olfactory testing (Sniffin' Sticks odor identification test) was performed at baseline and at 1, 2, and 3 months. The primary outcome was recovery of over three points on olfactory testing, with outcomes compared at T0, T1, T2 and T3 across groups. Statistical analyses included one-way ANOVA for numeric data and chi-square for nominal data.
RESULTS: All patients completed the study, and there were no adverse events. At 90 days, odor identification scores improved by > 3 points in 89.2% of patients receiving combined therapy vs. 36.8% receiving olfactory training with placebo, 40% receiving twice daily um-PEA-LUT alone, and 41.6% receiving once daily um-PEA-LUT alone (p < 0.00001). Patients receiving treatment with um-PEA-LUT alone demonstrated subclinical improvement (< 3 point odor identification improvement) more often than patients receiving olfactory training with placebo (p < 0.0001.) CONCLUSIONS: Olfactory training plus once daily um-PEA-LUT resulted in greater olfactory recovery than either therapy alone in patients with long-term olfactory function due to COVID-19.
TRIAL REGISTRATION: 20112020PGFN on clinicaltrials.gov.
LEVEL OF EVIDENCE: 1b (Individual Randomized Clinical Trial).
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:280 |
|---|---|
| Enthalten in: |
European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery - 280(2023), 11 vom: 28. Nov., Seite 4949-4961 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Di Stadio, Arianna [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 10.10.2023 Date Revised 29.12.2023 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1007/s00405-023-08085-8 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM358822009 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM358822009 | ||
| 003 | DE-627 | ||
| 005 | 20240108135902.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s00405-023-08085-8 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1242.xml |
| 035 | |a (DE-627)NLM358822009 | ||
| 035 | |a (NLM)37380908 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Di Stadio, Arianna |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Treatment of COVID-19 olfactory dysfunction with olfactory training, palmitoylethanolamide with luteolin, or combined therapy |b a blinded controlled multicenter randomized trial |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 10.10.2023 | ||
| 500 | |a Date Revised 29.12.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2023. The Author(s). | ||
| 520 | |a PURPOSE: Few evidence-based therapies are available for chronic olfactory dysfunction after COVID-19. This study investigated the relative efficacy of olfactory training alone, co-ultramicronized palmitoylethanolamide with luteolin (um-PEA-LUT, an anti-neuroinflammatory supplement) alone, or combined therapy for treating chronic olfactory dysfunction from COVID-19 | ||
| 520 | |a METHODS: This double-blinded controlled, placebo-controlled multicenter randomized clinical trial was conducted in 202 patients with persistent COVID-19 olfactory dysfunction of > 6 month duration. After a screening nasal endoscopy, patients were randomized to: (1) olfactory training and placebo; (2) once daily um-PEA-LUT alone; (3) twice daily um-PEA-LUT alone; or (4) combination of once daily um-PEA-LUT with olfactory training. Olfactory testing (Sniffin' Sticks odor identification test) was performed at baseline and at 1, 2, and 3 months. The primary outcome was recovery of over three points on olfactory testing, with outcomes compared at T0, T1, T2 and T3 across groups. Statistical analyses included one-way ANOVA for numeric data and chi-square for nominal data | ||
| 520 | |a RESULTS: All patients completed the study, and there were no adverse events. At 90 days, odor identification scores improved by > 3 points in 89.2% of patients receiving combined therapy vs. 36.8% receiving olfactory training with placebo, 40% receiving twice daily um-PEA-LUT alone, and 41.6% receiving once daily um-PEA-LUT alone (p < 0.00001). Patients receiving treatment with um-PEA-LUT alone demonstrated subclinical improvement (< 3 point odor identification improvement) more often than patients receiving olfactory training with placebo (p < 0.0001.) CONCLUSIONS: Olfactory training plus once daily um-PEA-LUT resulted in greater olfactory recovery than either therapy alone in patients with long-term olfactory function due to COVID-19 | ||
| 520 | |a TRIAL REGISTRATION: 20112020PGFN on clinicaltrials.gov | ||
| 520 | |a LEVEL OF EVIDENCE: 1b (Individual Randomized Clinical Trial) | ||
| 650 | 4 | |a Randomized Controlled Trial | |
| 650 | 4 | |a Multicenter Study | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Anosmia | |
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a Clinical trial | |
| 650 | 4 | |a Coronavirus | |
| 650 | 4 | |a Hyposmia | |
| 650 | 4 | |a Luteolin | |
| 650 | 4 | |a Neuroinflammation | |
| 650 | 4 | |a Olfactory training | |
| 650 | 4 | |a PEA | |
| 650 | 4 | |a PEA–LUT | |
| 650 | 4 | |a Palmitoylethanolamide | |
| 650 | 4 | |a Post-acute sequelae of COVID-19 | |
| 650 | 4 | |a Randomized trial | |
| 650 | 4 | |a SARS-CoV-2 | |
| 650 | 4 | |a Smell disorders | |
| 650 | 7 | |a palmidrol |2 NLM | |
| 650 | 7 | |a 6R8T1UDM3V |2 NLM | |
| 650 | 7 | |a Luteolin |2 NLM | |
| 650 | 7 | |a KUX1ZNC9J2 |2 NLM | |
| 700 | 1 | |a Gallina, Salvatore |e verfasserin |4 aut | |
| 700 | 1 | |a Cocuzza, Salvatore |e verfasserin |4 aut | |
| 700 | 1 | |a De Luca, Pietro |e verfasserin |4 aut | |
| 700 | 1 | |a Ingrassia, Angelo |e verfasserin |4 aut | |
| 700 | 1 | |a Oliva, Simone |e verfasserin |4 aut | |
| 700 | 1 | |a Sireci, Federico |e verfasserin |4 aut | |
| 700 | 1 | |a Camaioni, Angelo |e verfasserin |4 aut | |
| 700 | 1 | |a Ferreli, Fabio |e verfasserin |4 aut | |
| 700 | 1 | |a Mercante, Giuseppe |e verfasserin |4 aut | |
| 700 | 1 | |a Gaino, Francesca |e verfasserin |4 aut | |
| 700 | 1 | |a Pace, Gian Marco |e verfasserin |4 aut | |
| 700 | 1 | |a La Mantia, Ignazio |e verfasserin |4 aut | |
| 700 | 1 | |a Brenner, Michael J |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery |d 1994 |g 280(2023), 11 vom: 28. Nov., Seite 4949-4961 |w (DE-627)NLM012637548 |x 1434-4726 |7 nnns |
| 773 | 1 | 8 | |g volume:280 |g year:2023 |g number:11 |g day:28 |g month:11 |g pages:4949-4961 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1007/s00405-023-08085-8 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 280 |j 2023 |e 11 |b 28 |c 11 |h 4949-4961 | ||